For these studies, we used TRAF2DN/Bcl-2 mice that have developed leukemia, as indicated by the presence of a majority of CLL (FSCM B220M) cells in blood (over 4×106 B cells/ml). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.